IDXX vs INTS · P/E 40, rev $3.90B vs $7.7M cap
IDEXX Laboratories Inc (IDXX) versus Intensity Therapeutics, Inc. Common stock (INTS) — a side-by-side from cached financials, not a winner call.
IDEXX Laboratories Inc (IDXX) is a diagnostics & research company listed on NASDAQ.
Intensity Therapeutics, Inc. Common stock (INTS) is a biotechnology company listed on US.
Latest reported IDXX revenue for 2024-12-31 was $3.90B. Net income was $887.9M. Revenue was up 6.5% from 2023-12-31 to 2024-12-31. IDXX currently screens at market cap $43.08B and trailing P/E 40.2.
INTS does not have a complete income-statement cache yet.
IDXX currently screens at market cap $43.08B and trailing P/E 40.2. INTS currently screens at market cap $7.7M.
Not investment advice. Open the IDXX and INTS stock pages for the full models.
Not investment advice.